Hormonal
Perilipin (Plin) suppresses basal lipolysis by sequestering the co-activator Abhd5, preventing it from interacting with and activating Adipose Triglyceride Lipase (Atgl).
This research explains how your body regulates fat burning. In a resting state, a protein called Perilipin acts like a lock on your fat cells, holding back the enzyme (Abhd5) needed to break down fat. Hormones released during exercise (via PKA) unlock this system, releasing the enzyme to activate fat breakdown. This highlights why hormonal signals (like those from exercise or fasting) are crucial for mobilizing stored fat, not just caloric intake.
Sequestration of Abhd5 appears to a major mechanism by which Plin reduces basal lipolysis.
Why this rating
High-quality in vitro and cell-based evidence using multiple interaction assays (BiFC, FRET, luciferase complementation) and siRNA knockdowns.
Source
Perilipin Controls Lipolysis by Regulating the Interactions of AB-hydrolase Containing 5 (Abhd5) and Adipose Triglyceride Lipase (Atgl)
James G. Granneman et al. · Journal of Biological Chemistry · 2009
DOI 10.1074/jbc.m109.068478
More from this paper
- Phosphorylation of Perilipin at specific sites (Ser-492 and Ser-517) by PKA is required to release Abhd5, allowing it to interact with and activate Atgl, thereby stimulating lipolysis.Good
- Knockdown of Abhd5 reduces both basal and stimulated lipolysis, indicating that Abhd5 is essential for triglyceride breakdown independent of Hormone-Sensitive Lipase (HSL).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →